Scarica l'app Stockscreener
29.34
1.94%
-0.58
Dopo l'orario di chiusura:
29.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Canada
Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com India
STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones - TradingView
STOK: Phase III Dravet therapy shows durable 75%+ seizure reduction and functional gains in long-term data - TradingView
Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics and Biogen Present Long-Term Clinical Data tha - The National Law Review
Stoke Therapeutics CMO Barry Ticho Executes 5,545 Share Sales Under 10b5-1 Plan - Kalkine Media
Stoke Therapeutics grants inducement options to new CSO - scanx.trade
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Biogen
Biogen Inc. - Via Ritzau
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock - MarketBeat
Stoke Therapeutics (STOK) CMO sells 5,545 shares under pre-set plan - Stock Titan
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation - Moomoo
The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock gains on Dravet data and Cantor conference plans - ad-hoc-news.de
BIIB News | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference - Yahoo Finance
Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP - MarketBeat
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome By Investing.com - Investing.com Nigeria
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome - Investing.com
57,784 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Deutsche Bank AG - marketbeat.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Palo Alto Investors LP Invests $2.77 Million in Stoke Therapeutics, Inc. $STOK - marketbeat.com
Jupiter Topco LLC Takes $59.36 Million Position in Stoke Therapeutics, Inc. $STOK - marketbeat.com
BlackRock Inc. Buys Shares of 5,877,357 Stoke Therapeutics, Inc. $STOK - marketbeat.com
Parkman Healthcare Partners LLC Takes Position in Stoke Therapeutics, Inc. $STOK - marketbeat.com
Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight - Yahoo Finance
STOK Reinstated by JP Morgan -- Price Target Set at $40 - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Goldminenunternehmen, Ross Stores, Stoke Therapeutics - TradingView
STOK Looks 225.6% Overvalued on GF Value™ - GuruFocus
Why is Stoke Therapeutics stock gaining today? By Investing.com - Investing.com Canada
Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 7.9%What's Next? - MarketBeat
Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke (STOK) Results Breakdown: The Available Earnings Metric Delivers a Miss in the Reported Period; Share Response: The Stock Records a 2.77% Increase in the Latest ReadingPerformance Review - Vinanet
Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics (STOK)? - simplywall.st
Stoke (STOK) Quarterly Figures: EPS Falls Short of Its Estimate for the Current Session; Share Move: The Stock Gains 2.64% in the Current UpdateLow Estimate Range - vinanet.vn
Stoke Therapeutics general counsel Allan sells $91,639 in stock By Investing.com - Investing.com Australia
Stoke therapeutics CMO Barry Ticho sells $152k in stock By Investing.com - Investing.com Australia
Stoke Therapeutics’ director Kaye sells $402,528 in shares By Investing.com - Investing.com Australia
Stoke Therapeutics general counsel Allan sells $91,639 in stock - Investing.com
Stoke Therapeutics’ director Kaye sells $402,528 in shares - Investing.com
Stoke therapeutics CMO Barry Ticho sells $152k in stock - Investing.com
Edward Md Kaye Sells 12,567 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells 4,767 Shares of Stock - MarketBeat
Stoke Therapeutics (STOK) insider sale tied to tax withholding - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) CMO gets 10,000 shares, sells some for taxes - Stock Titan
Stoke Therapeutics (STOK) director share sale tied to taxes - Stock Titan
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Stoke (STOK) Session-Level Review: Closes 0.70% Higher at $32.35 on the Day; Nearby Levels: Price Remains Between $30.73 Support and $33.97 Resistance on the DayEarnings Beat Stocks - Vinanet
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts - TradingView
Stoke Therapeutics (STOK) gets 6.5% stake disclosure from Lynx1 Capital - Stock Titan
Trading Systems Reacting to (STOK) Volatility - Stock Traders Daily
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):